The FY2025 (Dec) proxy of Ultragenyx Pharmaceutical names 19 peer companies for pay. Among Ultragenyx Pharmaceutical and these peers, CEO pay was 7th highest of 9 and total shareholder return was the lowest of 9.
7th highest of 9in Ultragenyx Pharmaceutical and its pay peers, FY2025 (Dec) by CEO pay:
$6.9M$33.2M
9th highest of 9in Ultragenyx Pharmaceutical and its pay peers, FY2025 (Dec) by total shareholder return:
$17$523
Pay peer group, FY2025 (Dec) proxy
| Exelixis | ||
| PTC Therapeutics | ||
| Halozyme Therapeutics | ||
| BridgeBio Pharma | ||
| INSMED | ||
| Ionis Pharmaceuticals | ||
| Alkermes plc. | ||
| Neurocrine Biosciences | ||
| Acadia Pharmaceuticals | Not disclosed | Not disclosed |
| Amicus Therapeutics | Not disclosed | Not disclosed |
| Apellis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Axsome Therapeutics | Not disclosed | Not disclosed |
| Blueprint Medicines Corporation | Not disclosed | Not disclosed |
| Corcept Therapeutics | Not disclosed | Not disclosed |
| Denali Therapeutics Inc. | Not disclosed | Not disclosed |
| Intra-Cellular Therapies Inc. | Not disclosed | Not disclosed |
| Jazz Pharmaceuticals | Not disclosed | Not disclosed |
| Sarepta Therapeutics, Inc. | Not disclosed | Not disclosed |
| Vericel | Not disclosed | Not disclosed |
;fill-rule:nonzero'/%3e%3cpath%20d='M1148.33%20186.308c58.75%20119.583%2018.75%20283.333-97.916%20430.416h138.333c104.583-146.25%20137.917-305.416%2072.917-430.416C1163.33-3.276%20872.914-51.609%20575.83%2057.141c262.084-84.583%20494.167-31.25%20572.5%20129.167'%20style='fill:url(%23svg__ptc-logo-color__b);fill-rule:nonzero'/%3e%3cpath%20d='M121.25%20447.558V94.224h152.5c63.75%200%20122.917%2032.084%20122.917%20105.417%200%2021.667-8.334%20107.5-138.334%20107.5h-45v140.417zm128.333-200.417c47.084%200%2054.584-30%2054.584-44.583%200-35-28.334-42.917-55.417-42.917h-35.417v87.5zM790.417%20270.891c0-72.083%2051.666-119.167%20122.083-119.167%2019.583%200%2035.417%203.75%2048.75%208.75l35.417-60.416c-32.5-10.834-72.084-14.584-95-14.584-130.417%200-207.084%2085-207.084%20189.584%200%20127.5%20105.417%20181.666%20196.667%20181.666%2043.333%200%2064.583-5.416%2078.75-9.583l42.917-74.167c-24.167%2010.417-59.584%2019.167-91.667%2019.167-92.083-.417-130.833-61.667-130.833-121.25M138.75%20526.308h-17.917v-16.25h53.75v15.833h-17.916v90.833h-18.334v-90.416zM192.917%20617.141V510.058h18.333v43.333h19.583v-43.333h18.334v106.666h-18.334v-47.5H211.25v47.5h-18.333zM274.167%20617.141V510.058h49.166v15.833H292.5v27.5h23.75v15.833H292.5v31.25h32.917v15.834h-51.25zM365.833%20617.141H347.5V510.058h25.833c20.417%200%2031.25%208.75%2031.25%2031.666%200%2017.084-6.666%2024.167-12.916%2027.084l15.416%2048.333h-18.75l-12.916-44.167c-2.5.417-6.25.417-9.584.417zm0-59.167h6.667c10%200%2013.75-3.75%2013.75-16.25%200-12.916-3.75-16.25-13.75-16.25h-6.667zM438.75%20617.141h-17.917l19.584-106.667h22.916l19.584%20106.667H465l-3.333-23.75h-20zm5.833-39.583h14.584l-7.084-45.834zM501.25%20617.141V510.058h26.25c22.5%200%2033.333%208.75%2033.333%2031.666%200%2022.917-10.416%2031.667-33.333%2031.667h-7.917v43.75zm18.333-59.167h7.084c12.083%200%2015.833-3.75%2015.833-16.25%200-12.916-3.75-16.25-15.833-16.25h-7.084zM579.583%20617.141V510.058h49.167v15.833h-30.833v27.5h23.75v15.833h-23.75v31.25h32.916v15.834h-51.25zM652.5%20510.058h18.333v80.416c0%207.917%202.917%2011.667%209.584%2011.667s9.583-3.75%209.583-11.667v-80.416h18.333v80c0%2018.333-10.833%2028.333-27.916%2028.333-17.5%200-27.917-10-27.917-28.333zM744.583%20526.308h-17.916v-16.25h53.75v15.833H762.5v90.833h-18.333v-90.416zM801.25%20617.141V510.058h18.333v106.666H801.25zM884.167%20545.891v-8.333c0-9.167-4.167-12.917-8.75-12.917-7.5%200-9.584%203.75-9.584%2011.667v54.166c0%207.917%202.5%2011.667%209.584%2011.667%206.666%200%208.75-3.75%208.75-10.833v-12.917H902.5v12.083c0%2015-8.75%2027.5-27.083%2027.5-19.167%200-27.917-12.083-27.917-27.5v-55c0-15%208.75-27.5%2027.917-27.5%2018.333%200%2027.083%2013.334%2027.083%2029.167v7.917h-18.333zM962.083%20536.724c-.833-9.166-5.416-11.666-9.583-11.666-5.833%200-9.167%203.75-9.167%2010.416%200%2018.334%2037.084%2027.084%2037.084%2055.834%200%2017.5-11.667%2027.5-29.167%2027.5-17.083%200-26.667-13.75-27.5-29.584l17.5-2.5c.833%2010.834%205%2016.25%2010.833%2016.25%206.25%200%2010.834-3.333%2010.834-9.583%200-21.25-37.084-26.667-37.084-57.5%200-17.083%2010.417-26.667%2028.334-26.667%2015%200%2023.75%2010.834%2025.416%2025.834zM511.25%20447.558v-283.75H410.417V94.224h293.75v69.584h-100v283.75zM1230.42%20589.224h9.583v27.5h5.833v-27.5h9.584v-4.583h-25zM1286.25%20584.641l-9.167%2023.75-9.166-23.75h-8.334v32.083H1265v-25.833l10.417%2025.417v.416h3.333l10.417-25.833v25.833h5.416v-32.083z'%20style='fill:%23373153;fill-rule:nonzero'/%3e%3cdefs%3e%3clinearGradient%20id='svg__ptc-logo-color__a'%20x1='0'%20x2='1'%20y1='0'%20y2='0'%20gradientTransform='rotate(84.319%20-153.165%20165.88)scale(432.1524)'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20offset='0'%20style='stop-color:%23f79f5d;stop-opacity:1'/%3e%3cstop%20offset='1'%20style='stop-color:%23e84c38;stop-opacity:1'/%3e%3c/linearGradient%3e%3clinearGradient%20id='svg__ptc-logo-color__b'%20x1='0'%20x2='1'%20y1='0'%20y2='0'%20gradientTransform='rotate(84.319%20352.385%20623.618)scale(432.1755)'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20offset='0'%20style='stop-color:%23f79f5d;stop-opacity:1'/%3e%3cstop%20offset='1'%20style='stop-color:%23e84c38;stop-opacity:1'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e)
19 companies
Changes by year
FY2025 (Dec) proxy
- AddedAxsome Therapeuticspay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of Axsome Therapeutics, Inc., Denali Therapeutics Inc. and Vericel Corporation and the removal of BioCryst Biopharmaceuticals, Inc., FibroGen, Inc. and Sage Therapeutics, Inc. due to misalignment with our market capitalization and the removal of BioMarin Biopharmaceutical Inc. who exceeded our market capitalization and revenue ranges
- AddedDenali Therapeutics Inc.pay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of Axsome Therapeutics, Inc., Denali Therapeutics Inc. and Vericel Corporation and the removal of BioCryst Biopharmaceuticals, Inc., FibroGen, Inc. and Sage Therapeutics, Inc. due to misalignment with our market capitalization and the removal of BioMarin Biopharmaceutical Inc. who exceeded our market capitalization and revenue ranges
- AddedVericelpay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of Axsome Therapeutics, Inc., Denali Therapeutics Inc. and Vericel Corporation and the removal of BioCryst Biopharmaceuticals, Inc., FibroGen, Inc. and Sage Therapeutics, Inc. due to misalignment with our market capitalization and the removal of BioMarin Biopharmaceutical Inc. who exceeded our market capitalization and revenue ranges
- RemovedBioCryst Biopharmaceuticals, Inc.pay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of Axsome Therapeutics, Inc., Denali Therapeutics Inc. and Vericel Corporation and the removal of BioCryst Biopharmaceuticals, Inc., FibroGen, Inc. and Sage Therapeutics, Inc. due to misalignment with our market capitalization and the removal of BioMarin Biopharmaceutical Inc. who exceeded our market capitalization and revenue ranges
- RemovedBioMarin Biopharmaceutical Inc.pay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of Axsome Therapeutics, Inc., Denali Therapeutics Inc. and Vericel Corporation and the removal of BioCryst Biopharmaceuticals, Inc., FibroGen, Inc. and Sage Therapeutics, Inc. due to misalignment with our market capitalization and the removal of BioMarin Biopharmaceutical Inc. who exceeded our market capitalization and revenue ranges
- RemovedFibroGen, Inc.pay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of Axsome Therapeutics, Inc., Denali Therapeutics Inc. and Vericel Corporation and the removal of BioCryst Biopharmaceuticals, Inc., FibroGen, Inc. and Sage Therapeutics, Inc. due to misalignment with our market capitalization and the removal of BioMarin Biopharmaceutical Inc. who exceeded our market capitalization and revenue ranges
- RemovedIntra-Cellular Therapeuticspay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of ADMA Biologics, Inc., BioCryst Biopharmaceuticals, Inc., Madrigal Pharmaceuticals Inc. and Mirum Pharmaceuticals, Inc. and the removal of Exelixis Inc., Insmed Incorporated and Neurocrine Biosciences, Inc. from our 2025 peer group due to misalignment with our market capitalization and/or revenue and the removal of Intra-Cellular Therapeutics as it was acquired during the year
- RemovedSage Therapeutics, Inc.pay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of Axsome Therapeutics, Inc., Denali Therapeutics Inc. and Vericel Corporation and the removal of BioCryst Biopharmaceuticals, Inc., FibroGen, Inc. and Sage Therapeutics, Inc. due to misalignment with our market capitalization and the removal of BioMarin Biopharmaceutical Inc. who exceeded our market capitalization and revenue ranges
FY2024 (Dec) proxy
- AddedBridgeBio Pharmapay peer groupfollowing 20 companies in the pharmaceutical and biotechnology industries, reflecting the removal of Alnylam Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Ltd., Global Blood Therapeutics, Inc. and United Therapeutics Corporation from our peer group used to evaluate compensation for our named executive officers in 2023 in order to add BridgeBio Pharma, Inc. Intra-Cellular Therapies Inc. and Sage Therapeutics, Inc. who our Compensation Committee determined better fit the balanced criteria described above
- AddedIntra-Cellular Therapies Inc.pay peer groupfollowing 20 companies in the pharmaceutical and biotechnology industries, reflecting the removal of Alnylam Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Ltd., Global Blood Therapeutics, Inc. and United Therapeutics Corporation from our peer group used to evaluate compensation for our named executive officers in 2023 in order to add BridgeBio Pharma, Inc. Intra-Cellular Therapies Inc. and Sage Therapeutics, Inc. who our Compensation Committee determined better fit the balanced criteria described above
- AddedSage Therapeutics, Inc.pay peer groupfollowing 20 companies in the pharmaceutical and biotechnology industries, reflecting the removal of Alnylam Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Ltd., Global Blood Therapeutics, Inc. and United Therapeutics Corporation from our peer group used to evaluate compensation for our named executive officers in 2023 in order to add BridgeBio Pharma, Inc. Intra-Cellular Therapies Inc. and Sage Therapeutics, Inc. who our Compensation Committee determined better fit the balanced criteria described above
- RemovedAlnylam Pharmaceuticalspay peer groupfollowing 20 companies in the pharmaceutical and biotechnology industries, reflecting the removal of Alnylam Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Ltd., Global Blood Therapeutics, Inc. and United Therapeutics Corporation from our peer group used to evaluate compensation for our named executive officers in 2023 in order to add BridgeBio Pharma, Inc. Intra-Cellular Therapies Inc. and Sage Therapeutics, Inc. who our Compensation Committee determined better fit the balanced criteria described above
- RemovedBioMarin Biopharmaceutical Inc.pay peer groupfollowing 19 companies in the pharmaceutical and biotechnology industries, reflecting the addition of Axsome Therapeutics, Inc., Denali Therapeutics Inc. and Vericel Corporation and the removal of BioCryst Biopharmaceuticals, Inc., FibroGen, Inc. and Sage Therapeutics, Inc. from our 2024 peer group due to misalignment with our market capitalization and the removal of BioMarin Biopharmaceutical Inc. who exceeded our market capitalization and revenue ranges
- RemovedBiohaven Pharmaceutical Holding Company, Ltd.pay peer groupfollowing 20 companies in the pharmaceutical and biotechnology industries, reflecting the removal of Alnylam Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Ltd., Global Blood Therapeutics, Inc. and United Therapeutics Corporation from our peer group used to evaluate compensation for our named executive officers in 2023 in order to add BridgeBio Pharma, Inc. Intra-Cellular Therapies Inc. and Sage Therapeutics, Inc. who our Compensation Committee determined better fit the balanced criteria described above
- RemovedGlobal Blood Therapeutics, Inc.pay peer groupfollowing 20 companies in the pharmaceutical and biotechnology industries, reflecting the removal of Alnylam Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Ltd., Global Blood Therapeutics, Inc. and United Therapeutics Corporation from our peer group used to evaluate compensation for our named executive officers in 2023 in order to add BridgeBio Pharma, Inc. Intra-Cellular Therapies Inc. and Sage Therapeutics, Inc. who our Compensation Committee determined better fit the balanced criteria described above
- RemovedUnited Therapeuticspay peer groupfollowing 20 companies in the pharmaceutical and biotechnology industries, reflecting the removal of Alnylam Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Ltd., Global Blood Therapeutics, Inc. and United Therapeutics Corporation from our peer group used to evaluate compensation for our named executive officers in 2023 in order to add BridgeBio Pharma, Inc. Intra-Cellular Therapies Inc. and Sage Therapeutics, Inc. who our Compensation Committee determined better fit the balanced criteria described above
'%20fill='none'%20fill-rule='evenodd'%3e%3cpath%20d='M7.497%2029.085s2.985.806%203.69-.538c1.658-3.153-3.086-13.225-3.086-13.225s5.502%2013.038%2011.82%2019.07c3.464%203.305%207.438%203.503%2010.166%201.999%205.572-3.077%2013.026-18.379%2013.854-19.916.829-1.539-5.422%2013.84-7.605%2017.3-2.183%203.462-4.066%207.458-11.143%207.69-8.462.275-17.696-12.38-17.696-12.38'%20fill='%230F9BD7'/%3e%3cg%20transform='translate(0%2016.123)'%3e%3cmask%20id='iz0ij2keyb'%20fill='%23fff'%3e%3cuse%20xlink:href='%23bbe95veu1a'/%3e%3c/mask%3e%3cpath%20d='M0%203.043C0%201.363%201.333%200%202.98%200c1.645%200%202.977%201.363%202.977%203.043%200%201.68-1.332%203.042-2.977%203.042C1.333%206.085%200%204.722%200%203.043'%20fill='%23ACD5F1'%20mask='url(%23iz0ij2keyb)'/%3e%3c/g%3e%3cg%20transform='translate(7.873)'%3e%3cmask%20id='vrpx36r1md'%20fill='%23fff'%3e%3cuse%20xlink:href='%23bwovqcdwic'/%3e%3c/mask%3e%3cpath%20d='M13.028%204.171s2.184-.77%202.484-.384c.63.804.528%201.614-1.206%203.614-1.73%201.999-6.7%207.304-6.7%207.304s10.186-9.316%2013.025-8.38c2.336.768%201.358%204.152.98%205.381-.377%201.231-4.97%2013.919-21.61%2040.292-.182.29%2024.462-29.757%2025.525-42.52.903-10.843-4.292-9.46-4.669-9.38-4.411.9-7.83%204.073-7.83%204.073'%20fill='%231A3967'%20mask='url(%23vrpx36r1md)'/%3e%3c/g%3e%3cpath%20d='M64.023%2029.175%2058.52%2015.877l-5.502%2013.298h11.005zm-5.964-17.374h.923L71.5%2041.356h-2.437l-4.243-10.209H52.22l-4.242%2010.21h-2.436L58.06%2011.8z'%20fill='%231A3967'/%3e%3cmask%20id='7uez1t42pf'%20fill='%23fff'%3e%3cuse%20xlink:href='%23z9efbhhede'/%3e%3c/mask%3e%3cpath%20fill='%231A3967'%20mask='url(%237uez1t42pf)'%20d='M75.616%2041.356h2.142V12.06h-2.142zM83.977%2022.011h2.1V25.1c1.806-2.275%203.948-3.433%206.551-3.433%204.285%200%206.722%202.832%206.722%207.893v11.798h-2.1V30.59c0-4.634-1.554-6.949-4.831-6.949-2.604%200-4.748%201.374-6.343%204.074v13.643h-2.1V22.01zM102.625%2022.011h2.352L111.7%2035.18l6.3-13.168h2.184L106.24%2051.095h-2.142l6.467-13.513zM123.46%2041.356h2.144V12.06h-2.145zM141.06%2031.404c-5.712.087-8.863%202.318-8.863%205.32%200%201.974%201.387%203.217%203.698%203.217%201.638%200%203.276-.857%205.166-2.487v-6.05zm-5.755%2010.38c-3.148%200-5.25-2.058-5.25-4.975%200-4.203%203.78-6.82%2011.006-7.12v-2.058c0-2.875-1.262-4.161-4.242-4.161-1.933%200-3.74.815-5.799%202.359v-2.103c2.06-1.415%203.992-2.144%205.965-2.144%204.454%200%206.177%202.06%206.177%206.562v10.124c0%20.856.21%201.245.672%201.245.587%200%201.133-.602%202.14-1.501v1.972c-1.216%201.159-2.266%201.76-3.066%201.76-1.218%200-1.723-.688-1.804-2.276-1.975%201.546-3.699%202.317-5.799%202.317zM149.335%2022.011h2.102V25.1c1.722-2.275%203.78-3.433%206.299-3.433%202.815%200%204.58%201.158%205.881%203.947%202.059-2.66%204.16-3.947%206.806-3.947%204.117%200%206.468%202.832%206.468%207.893v11.798h-2.142V30.59c0-4.634-1.47-6.949-4.579-6.949-2.478%200-4.537%201.374-6.006%204.074v13.643h-2.1V30.59c0-4.634-1.513-6.949-4.621-6.949-2.48%200-4.494%201.374-6.006%204.074v13.643h-2.102V22.01zM179.884%2019.427v1.083h.569c.602%200%20.86-.113.86-.558%200-.37-.285-.525-.86-.525h-.569zm1.826.539c0%20.403-.264.708-.687.757l.645%201.362h-.446l-.616-1.305h-.722v1.305h-.388v-2.928h1.034c.789%200%201.18.241%201.18.809zm.33-.916a2.192%202.192%200%200%200-1.587-.67c-.603%200-1.152.232-1.56.656a2.335%202.335%200%200%200-.666%201.622c0%20.603.236%201.169.66%201.603.421.433.975.672%201.566.672.582%200%201.152-.24%201.588-.679.417-.418.645-.97.645-1.596%200-.615-.228-1.182-.645-1.608zm.176-.177c.464.477.713%201.108.713%201.785%200%20.696-.249%201.305-.713%201.771a2.469%202.469%200%200%201-1.763.758c-.66%200-1.27-.266-1.74-.748a2.517%202.517%200%200%201-.73-1.78c0-.666.257-1.302.736-1.798a2.365%202.365%200%200%201%201.734-.73c.673%200%201.29.263%201.763.742z'/%3e%3c/g%3e%3c/svg%3e)
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.